ATE135690T1 - Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems - Google Patents

Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems

Info

Publication number
ATE135690T1
ATE135690T1 AT92901652T AT92901652T ATE135690T1 AT E135690 T1 ATE135690 T1 AT E135690T1 AT 92901652 T AT92901652 T AT 92901652T AT 92901652 T AT92901652 T AT 92901652T AT E135690 T1 ATE135690 T1 AT E135690T1
Authority
AT
Austria
Prior art keywords
nervous system
central nervous
agents
hydroxypiperidines
treatment
Prior art date
Application number
AT92901652T
Other languages
English (en)
Inventor
Shelly Glase
Juan Carlos Jaen
Sarah Jane Smith
Lawrence David Wise
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE135690T1 publication Critical patent/ATE135690T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT92901652T 1990-11-05 1991-10-29 Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems ATE135690T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60927490A 1990-11-05 1990-11-05
US07/778,248 US5273977A (en) 1990-11-05 1991-10-24 Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents

Publications (1)

Publication Number Publication Date
ATE135690T1 true ATE135690T1 (de) 1996-04-15

Family

ID=27085995

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92901652T ATE135690T1 (de) 1990-11-05 1991-10-29 Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems

Country Status (11)

Country Link
US (3) US5273977A (de)
EP (1) EP0556332B1 (de)
JP (1) JP3047470B2 (de)
AT (1) ATE135690T1 (de)
AU (1) AU670532B2 (de)
CA (1) CA2094702C (de)
DE (1) DE69118198T2 (de)
DK (1) DK0556332T3 (de)
ES (1) ES2084339T3 (de)
GR (1) GR3019782T3 (de)
WO (1) WO1992007831A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273977A (en) * 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
DE4425145A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
GB9523462D0 (en) * 1995-11-16 1996-01-17 Merck Sharp & Dohme Therapeutic agents
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
EP0974584B1 (de) * 1997-02-21 2003-01-15 Takeda Chemical Industries, Ltd. Verbindungen mit kondensierten ringen, verfahren zu ihrer herstellung und ihre anwendung
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
JP2003506387A (ja) * 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド カリウムチャンネルオープナーとしてのベンズアニリド
NZ527771A (en) * 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
IL149250A0 (en) * 1999-10-22 2002-11-10 Sanofi Synthelabo Phenyl-and pyridyl-tetrahydro-pyridines having tnf inhibiting activity
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
WO2009120720A1 (en) * 2008-03-24 2009-10-01 Medivation Technologies,Inc. Bridged heterocyclic compounds and methods of use
JP5869484B2 (ja) * 2009-09-23 2016-02-24 メディベイション テクノロジーズ， インコーポレイテッド 架橋複素環化合物およびその使用
US8859561B2 (en) 2009-09-23 2014-10-14 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
ES2689956T3 (es) * 2010-11-05 2018-11-16 Oat Agrio Co., Ltd. Compuesto de etinilfenilamidina o sal del mismo, procedimiento para producir el mismo y fungicida para una utilización agrícola y hortícola
BR112013021126A2 (pt) 2011-02-18 2019-09-24 Medivation Technologies Inc método para reduzir a pressão sanguínea, método para aumentar o fluxo sanguíneo renal ou diminuir a reabsorção de sódio, método para tratar uma doença, kit, composto e composição farmacêutica
WO2016192657A1 (en) 2015-06-03 2016-12-08 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633474A (de) *
GB1055548A (en) * 1965-08-23 1967-01-18 Acraf New substituted 1-aryl-3-aminopropynes and process for their preparation
FR1490501A (fr) * 1966-02-23 1967-08-04 Docteur Jacques Auciair Lab Du Nouveaux dérivés du butyne-2 et leur procédé de préparation
US4208415A (en) * 1978-02-06 1980-06-17 E. R. Squibb & Sons, Inc. 4-[2-(2-Substituted phenyl)ethenyl]-N-alkenyl or alkinyl substituted 1,2,3,6-tetrahydropyridines
AU593194B2 (en) * 1986-09-26 1990-02-01 Sumitomo Pharmaceuticals Company, Limited Imide derivatives ,and their production and use
AU658134B2 (en) * 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US5034392A (en) * 1990-04-16 1991-07-23 Hoechst-Roussel Pharmaceuticals Incorporated 4-(3-(4-oxothiazolidinyl)butynylamines
US5273977A (en) * 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents

Also Published As

Publication number Publication date
EP0556332A1 (de) 1993-08-25
DE69118198T2 (de) 1996-11-14
DE69118198D1 (de) 1996-04-25
WO1992007831A1 (en) 1992-05-14
AU9123191A (en) 1992-05-26
CA2094702A1 (en) 1992-05-06
US5620988A (en) 1997-04-15
JPH06501952A (ja) 1994-03-03
CA2094702C (en) 2002-02-12
GR3019782T3 (en) 1996-07-31
JP3047470B2 (ja) 2000-05-29
US5273977A (en) 1993-12-28
EP0556332B1 (de) 1996-03-20
US5466698A (en) 1995-11-14
ES2084339T3 (es) 1996-05-01
DK0556332T3 (da) 1996-06-03
AU670532B2 (en) 1996-07-25

Similar Documents

Publication Publication Date Title
DE69118198D1 (de) Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems
MY107728A (en) Substituted cyclohexanols as central nervous system agents.
BG100830A (en) Naphthylamides as central nervous system agents
TR199900255T2 (xx) Muskarinik antagonistleri
ATE418986T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems welche einen nicotin-analog und einen acetylcholinesterase inhibitor enthalten
NO961687D0 (no) Nye (R)-5-karbamoyl-8-fluor-3-N,N-disubstituerte-amino-3,4-dihydro-2H-1-benzopyraner
NO180632C (no) 1,3-substituerte cykloalkener og cykloalkaner som sentralnervesystem-midler
ATE132855T1 (de) Substituierte piperazine als mittel zur behandlung des zentrallen nervensystems
MY107354A (en) Substituted cyclohexenes as central nervous system agents
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
MX9302225A (es) Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee